BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Sells $26,668.74 in Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Troy Wichterman sold 987 shares of the company’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $27.02, for a total value of $26,668.74. Following the completion of the sale, the chief financial officer now owns 121,779 shares of the company’s stock, valued at approximately $3,290,468.58. The trade was a 0.80 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Troy Wichterman also recently made the following trade(s):

• On Tuesday, November 26th, Troy Wichterman sold 581 shares of BioLife Solutions stock. The shares were sold at an average price of $27.20, for a total value of $15,803.20.
• On Tuesday, November 12th, Troy Wichterman sold 147 shares of BioLife Solutions stock. The shares were sold at an average price of $26.19, for a total value of $3,849.93.
• On Wednesday, October 30th, Troy Wichterman sold 894 shares of BioLife Solutions stock. The shares were sold at an average price of $23.15, for a total value of $20,696.10.

BioLife Solutions Stock Up 2.1 %

BLFS stock traded up $0.58 during mid-day trading on Wednesday, reaching $27.69. The company had a trading volume of 270,111 shares, compared to its average volume of 217,162. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78. The company has a market capitalization of $1.28 billion, a price-to-earnings ratio of -26.12 and a beta of 1.92. The firm has a fifty day simple moving average of $25.91 and a 200 day simple moving average of $24.27. BioLife Solutions, Inc. has a fifty-two week low of $14.50 and a fifty-two week high of $28.88.

Institutional Investors Weigh In On BioLife Solutions

A number of hedge funds have recently bought and sold shares of BLFS. Mark Sheptoff Financial Planning LLC acquired a new stake in BioLife Solutions in the 3rd quarter valued at about $28,000. Quest Partners LLC purchased a new position in shares of BioLife Solutions in the 3rd quarter valued at about $57,000. GAMMA Investing LLC increased its holdings in shares of BioLife Solutions by 29.4% in the 3rd quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider’s stock valued at $83,000 after acquiring an additional 748 shares during the last quarter. Canada Pension Plan Investment Board purchased a new position in shares of BioLife Solutions in the 2nd quarter valued at about $122,000. Finally, Arizona State Retirement System purchased a new position in shares of BioLife Solutions in the 2nd quarter valued at about $217,000. Institutional investors and hedge funds own 93.24% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently commented on BLFS shares. HC Wainwright decreased their price target on BioLife Solutions from $29.00 to $27.00 and set a “buy” rating on the stock in a research note on Monday, November 18th. Benchmark reaffirmed a “buy” rating and issued a $30.00 price target on shares of BioLife Solutions in a research note on Thursday, December 19th. TD Cowen upped their price target on BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Northland Securities increased their target price on BioLife Solutions from $28.00 to $31.00 and gave the stock an “outperform” rating in a research note on Wednesday. Finally, KeyCorp increased their target price on BioLife Solutions from $30.00 to $33.00 and gave the stock an “overweight” rating in a research note on Friday, December 13th. One analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. Based on data from MarketBeat, BioLife Solutions presently has a consensus rating of “Moderate Buy” and an average target price of $29.43.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.